Synthesis and pharmacological profile of 6-methyl-3-isopropyl-2H-1,2-benzothiazin-4(3H)-one 1,1-dioxide derivatives: Non-steroidal anti-inflammatory agents with reduced ulcerogenic effects in the rat

European Journal of Pharmaceutical Sciences

Volumn 16, Issue 4-5, 2002, Pages 221-228

  Kacem, Yakdhane ^a   Kraiem, Jamil ^a   Kerkeni, Emna ^b   Bouraoui, Abderrahman ^b   Ben Hassine, Béchir ^a  

^a FACULTÉ DES SCIENCES DE MONASTIR   (Tunisia)

^b UNIVERSITY OF MONASTIR   (Tunisia)

Author keywords

Non steroidal anti inflammatory; Piroxicam; Rat; Synthesis; Ulcerogenic

Indexed keywords

ASSAYS; ORGANIC COMPOUNDS; PH EFFECTS; SPECTRUM ANALYSIS; SYNTHESIS (CHEMICAL);

INFLAMMATORY AGENTS;

DRUG PRODUCTS;

2,6 DIMETHYL 3 ISOPROPYL 1,2 BENZOTHIAZIN 4(3H) OL 1,1 DIOXIDE; 2,6 DIMETHYL 3 ISOPROPYL 1,2 BENZOTHIAZIN 4(3H) ONE 1,1 DIOXIDE; 2,6 DIMETHYL 3 ISOPROPYL 3 HYDROXY 1,2 BENZOTHIAZIN 3,4 DIOL 1,1 DIOXIDE; 2,6 DIMETHYL 3 ISOPROPYL 3 HYDROXY 1,2 BENZOTHIAZIN 4 ONE 1,1 DIOXIDE; 6 METHYL 3 ISOPROPYL 2H 1,2 BENZOTHIAZIN 4(3H) OL 1,1 DIOXIDE; 6 METHYL 3 ISOPROPYL 2H 1,2 BENZOTHIAZIN 4(3H) ONE 1,1 DIOXIDE; CARRAGEENAN; KETONE; NITROGEN; NONSTEROID ANTIINFLAMMATORY AGENT; OXIDE; PIROXICAM; SULFONAMIDE; UNCLASSIFIED DRUG;

ALBINISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG POTENCY; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERANCE; FEMALE; GASTROINTESTINAL TRACT; MALE; MOUSE; NONHUMAN; PAW EDEMA; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RAT; SPECTROMETRY; STOMACH CONTENT; STOMACH PH; STRUCTURE ACTIVITY RELATION; ULCEROGENESIS;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARRAGEENAN; CYCLIC S-OXIDES; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; EDEMA; FEMALE; GASTRIC ACID; GASTRIC ACIDITY DETERMINATION; INJECTIONS, INTRAPERITONEAL; LETHAL DOSE 50; MALE; MICE; RATS; RATS, WISTAR; STOMACH ULCER; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZINES; VALINE;

EID: 0036743318     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-0987(02)00046-5     Document Type: Article

References (29)

1. Bakker, W.I.I., Familoni, O.B., Padfield, J., Snieckus, V., 1997. Intramolecular anionic Friedel-Crafts equivalents. An expeditious synthesis of 4H-1,2-benzothiazin-4-one 1,1-dioxides from N-arylsulfonylated amino acids. Synlett. 1079-1080.
2. Berg J., Fellier H., Christoph T., Grarup J., Stimmeder D. The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inductible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro. Inflamm. Res. 48:1999;369-379.
3. Binder D., Hromatka O., et al. Analogues and derivatives of tenoxicam. Synthesis and anti-inflammatory activity of analogues with different residues on the ring nitrogen and the amide nitrogen. J. Med. Chem. 30:1987;678-682.
4. Craig, D., Berry, M.B., 1992. A convenient method for the preparation of enantiomerically pure 2-substituted N-tosylaziridines. Synlett. 41-44.
5. Cryer B., Feldman M. Effects of non-steroidal anti-inflammatory drugs on endogenous GI prostaglandins and therapeutic strategies for prevention and treatment of non-steroidal anti-inflammatory drug-induced damage. Arch. Intern. Med. 152:1992;115.
6. Davis, F.A., Chen, B.-C., 1992. Asymmetric hydroxylation of enolates with N-sulfonyloxaziridines. 92, 919-934.
7. Davis F.A., Kumar A., Chen B.-C. Chemistry of oxaziridines 16. A short, highly enantioselective synthesis of the AB-ring segments of γ-rhodomycinone and α-citromycinone using (+)-[(8,8-dimethoxycamphoryl)sulfonyl]oxaziridine. J. Org. Chem. 56:1991;1143-1145.
8. Dequeker J., Hawkey C., et al. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the safety and efficacy large-scale evaluation of COX-inhibiting therapies (SELECT) trial in osteoarthritis. Br. J. Rheumatol. 37:1998;946-951.
9. Engelhardt G., Homma D., Schlegel K., Utzmann R., Schnitzler C. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favorable gastrointestinal tolerance. Inflamm. Res. 44:1995;423-433.
10. Farre A.J., Colombo M., Fort M., Gutierrez B., Rodriguez L., Roser R. Pharmacological properties of droxicam, a new non-steroidal anti-inflammatory agent. Methods Find. Exp. Clin. Pharmacol. 8:1986;407-422.
11. Freindinger R.M., Hinkle J.S., Perlow D.S., Arison B.H. Synthesis of 9-fluorenylmethyloxycarbonyl-protected N-alkyl amino acids by reduction of oxazolidinones. J. Org. Chem. 48:1983;77-81.
12. Kraïem J., Kacem Y., Khiari J., Ben Hassine B. Stereospecific synthesis of 2-alkyl-3-aryloxaziridines from prochiral and chiral N-arylidenealkylamines by use of the benzonitrile-hydrogen peroxide system. Synth. Commun. 31:2001;263-271.
13. Kulkarni S.K. Handbook of Experimental Pharmacology. 1993;69-71 Vallabh Prakashan Delhi.
14. Lee E.B., Kwon S.K., Kim S.G. Synthesis and analgesic and anti-inflammatory activities of 1,2-benzothiazine derivatives. Arch. Pharm. Res. 22:1999;44-47.
15. Lipscomb G.R., Wallis N., Armstrong G., Rees W.D. Gastrointestinal tolerability of meloxicam and piroxicam: a double-blind placebo-controlled study. Br. J. Clin. Pharmacol. 46:1998;133-137.
16. Litchfield J.T., Wilcoxon F.A. A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther. 96:1949;99-113.
17. Lombardino J.G., Wiseman E.H., Chiaini J. Potent anti-inflammatory N-heterocyclic 3-carboxamides of 4-hydroxy-2-methyl-2H-1,2-benzothiazine 1,1-dioxide. J. Med. Chem. 16:1972;493-496.
18. Main I.H.M., Whittle B.J.R. The effect of E and A prostaglandin on gastric mucosal blood flow and acid secretion in the rat. Br. J. Pharmacol. 49:1973;428.
19. Moote C. Efficacy of non-steroidal anti-inflammatory drugs in the management of postoperative pain. Drugs. 44:Suppl. 5 1992;14-30.
20. Nezamin R.J.E., Philips J.P. Inhibition of gastric secretion by prostaglandins. Am. J. Digest. Dis. 12:1967;1073-1076.
21. Scott L.J., Lamb H.M. Rofecoxib. Drugs. 58:1999;499-505.
22. Simon L.S., et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase-2 inhibitor. Arthritis Rheum. 41:1998;1591-1601.
23. Snieckus V. Directed ortho metalation. Tertiary amide and O-carbamate directors in synthetic strategies for polysubstituted aromatics. Chem. Rev. 90:1990;879-933.
24. Vane J.R., Botting R.M. New insights into the mode of action of anti-inflammatory drugs. Inflamm. Res. 44:1995;1-10.
25. Vane J.R., Botting R.M. Mechanism of action of anti-inflammatory drugs. Scand. J. Rheumatol. 25:1996;9-25.
26. Vane J.R., Botting R.M., Bakhle Y.S. Cyclooxygenases 1 and 2. Annu. Rev. Pharmacol. Toxicol. 38:1998;97-120.
27. Von Bruchhausen F., Ebel S., Frahm A.W. Handbuch der Pharmazeutischen Praxis. Vol. 7: 1993;Springer Heidelberg.
28. Winter C.A., Risley G.A., Nuss G.W. Carrageenan-induced oedema in hind paw of the rat as an assay for anti-inflammatory drugs. Proc. Soc. Exp. Biol. Med. 3:1962;544-547.
29. Wiseman E.H., Chang Y.H., Lombardino J.G. Piroxicam, a novel anti-inflammatory agent. Arzneim.-Forsch. 26:1976;1300-1303.